Literature DB >> 27144932

Longitudinal Associations of Phospholipid and Cholesteryl Ester Fatty Acids With Disorders Underlying Diabetes.

Luke W Johnston1, Stewart B Harris1, Ravi Retnakaran1, Bernard Zinman1, Adria Giacca1, Zhen Liu1, Richard P Bazinet1, Anthony J Hanley1.   

Abstract

CONTEXT: Specific serum fatty acid (FA) profiles predict the development of incident type 2 diabetes; however, limited longitudinal data exist exploring their role in the progression of insulin sensitivity (IS) and β-cell function.
OBJECTIVE: To examine the longitudinal associations of the FA composition of serum phospholipid (PL) and cholesteryl ester (CE) fractions with IS and β-cell function over 6 years.
DESIGN: The Prospective Metabolism and Islet Cell Evaluation (PROMISE) cohort is a longitudinal observational study, with clinic visits occurring every 3 years. Three visits have been completed, totaling 6 years of follow-up.
SETTING: Individuals (n = 477) at risk for diabetes recruited from the general population in London and Toronto, Canada. MAIN OUTCOME MEASURES: Values from an oral glucose tolerance test were used to compute 1/HOMA-IR and the Matsuda index for IS, the insulinogenic index over HOMA-IR, and the insulin secretion-sensitivity index-2 for β-cell function. Thin-layer chromatograph and gas chromatograph quantified FA. Generalized estimating equations were used for the analysis.
RESULTS: IS and β-cell function declined by 8.3-19.4% over 6 years. In fully adjusted generalized estimating equation models, PL cis-vaccenate (18:1n-7) was positively associated with all outcomes, whereas γ-linolenate (GLA; 18:3n-6) and stearate (18:0) were negatively associated with IS. Tests for time interactions revealed that PL eicosadienoate (20:2n-6) and palmitate (16:0) and CE dihomo-γ-linolenate (20:3n-6), GLA, and palmitate had stronger associations with the outcomes after longer follow-up.
CONCLUSIONS: In a Canadian population at risk for diabetes, we found that higher PL stearate and GLA and lower cis-vaccenic acid predicted consistently lower IS and β-cell function over 6 years.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27144932     DOI: 10.1210/jc.2015-4267

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Circulating omega-7 fatty acids are differentially related to metabolic dysfunction and incident type II diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  N L Weir; B T Steffen; W Guan; L M Johnson; L Djousse; K J Mukamal; M Y Tsai
Journal:  Diabetes Metab       Date:  2019-11-06       Impact factor: 6.041

2.  Association of NEFA composition with insulin sensitivity and beta cell function in the Prospective Metabolism and Islet Cell Evaluation (PROMISE) cohort.

Authors:  Luke W Johnston; Stewart B Harris; Ravi Retnakaran; Adria Giacca; Zhen Liu; Richard P Bazinet; Anthony J Hanley
Journal:  Diabetologia       Date:  2017-12-24       Impact factor: 10.122

3.  Clusters of fatty acids in the serum triacylglyceride fraction associate with the disorders of type 2 diabetes.

Authors:  Luke W Johnston; Zhen Liu; Ravi Retnakaran; Bernard Zinman; Adria Giacca; Stewart B Harris; Richard P Bazinet; Anthony J Hanley
Journal:  J Lipid Res       Date:  2018-07-09       Impact factor: 5.922

4.  Circ-Tulp4 promotes β-cell adaptation to lipotoxicity by regulating soat1 expression.

Authors:  Liting Wu; Li Xiong; Jin Li; Zishan Peng; Luyao Zhang; Peijie Shi; Yingying Gong; Haipeng Xiao
Journal:  J Mol Endocrinol       Date:  2020-11       Impact factor: 5.098

5.  Integrative Analysis of Lipid Profiles in Plasma Allows Cardiometabolic Risk Factor Clustering in Children with Metabolically Unhealthy Obesity.

Authors:  Elena Cristina Castillo; Leticia Elizondo-Montemayor; Carmen Hernández-Brenes; Dariana G Rodríguez-Sánchez; Christian Silva-Platas; Luis Martín Marín-Obispo; Nora A Rodríguez-Gutierrez; Víctor Treviño; Gerardo García-Rivas
Journal:  Oxid Med Cell Longev       Date:  2020-08-11       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.